Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire•16/11/2026•07:01 ET
0
Key Highlights
- ➤$142.7 million cash, equivalents, restricted cash and securities fund operations into Q2 2028
- ➤PRT13722 Phase 1 enrollment began in Q4 2026; proof-of-concept data expected H2 2027
- ➤Lilly agreement adds abemaciclib and imlunestrant combinations to PRT13722’s Phase 1 trial
- ➤PRT12396 Phase 1 continues enrolling patients with polycythemia vera and myelofibrosis
- ➤Q3 net loss $12.5 million, or $0.12 per share, versus $19.7 million previously
Expert Statements
Kris Vaddi, Chief Executive Officer of Prelude Therapeutics
“The first three quarters of 2026 have been a period of strong execution for Prelude. We rapidly advanced two potential first-in-class programs into clinical development including PRT12396, a mutant-selective JAK2V617F inhibitor with disease-modifying potential in myeloproliferative neoplasms (MPNs) and PRT13722, a selective KAT6A degrader with the potential to improve the safety and efficacy of KAT6 inhibition, a clinically validated approach in HR+ breast cancer. In addition, we advanced our first-in-class mCALR degrader antibody conjugate (DAC) program into preclinical development with the selection of the development candidate, for mCALR+ MPNs, and we look forward to presenting its first preclinical data at ASH in December. With multiple clinical readouts expected over the next 12 to 18 months, we are well positioned to enter 2027 with the momentum to drive future growth of Prelude.”
Enrollment of Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer is underway; initial proof of concept data anticipated in the 2(nd) half of 2027
Entered into a clinical trial collaboration and supply agreement with Lilly to evaluate PRT13722 in combination with Verzenio(® )and Inluriyo(®) in patients with HR+/HER2- breast cancer
Get started
Create a free account to read the full story.
